Stay updated on Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:39:01.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the enrollment number of participants with relapsed or refractory follicular lymphoma in the study comparing Loncastuximab Tesirine to Idelalisib.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:22.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as age, health conditions, and prior treatments. Previously, no information was provided in this section.
    Difference
    47%
    Check dated 2024-05-22T20:54:03.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:12.000Z thumbnail image

Stay in the know with updates to Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page.